


8 Sep 2026 · 26m · 11 chapters

How the two new oral GLP-1 weight-loss drugs work—oral semaglutide vs orforglipron—and why “pill vs injection” doesn’t change core metabolism (insulin-driven fat storage/release).
No podcast guest; the episode is taught by Ben Bickman (metabolic scientist and cell biology professor).
Oral semaglutide is a peptide that must be protected from stomach acid using SNAC; it requires an empty stomach, minimal water, and has low absorption (~1%). Orforglipron (small molecule, Foundeo) survives digestion, activates the GLP-1 receptor at a different attachment point, is ~80% absorbed, and can be taken with food once daily.
26-week type 2 diabetes trial (orforglipron vs placebo and injectable GLP-1) improved insulin resistance ~25% and increased adiponectin; obesity trial (~3,000 adults, 72 weeks) showed weight loss ~7.5–11% (orforglipron) vs ~2% placebo; head-to-head vs oral semaglutide favored orforglipron for blood sugar/weight at tested doses.
Written by AI. May contain mistakes.
Learn about the differences between injectable and oral GLP-1 drugs.
“Are GLP-1 pills just injectable drugs turned into tablets?”
Get a thorough understanding of GLP-1 and its role in metabolism.
“Welcome back to the Metabolic Classroom.”
Explore the differences between oral semaglutide and orforaglipron.
“The pH is extremely low, which means it's very acidic, like roughly similar to the acidity of battery acid.”
Learn how orforaglipron works differently from semaglutide.
“Orforaglipron, this is sold as a drug called Foundeo by Lilly.”
Learn about the absorption rates and dosage benefits of orforaglipron.
“So orforaglipron was labeled or tagged in a way as a molecule that they could see where it goes in the body.”
Understand how insulin affects fat cells and weight loss drugs.
“They can take it any time of the day with any amount of food.”
Explore the outcomes of trials comparing orforaglipron and semaglutide.
“and just over 11 % at the highest dose against a loss of just about 2 % on placebo.”
Discuss how weight maintenance differs between orforaglipron and placebo.
“So pretty good, pretty comparable weight loss.”
Learn how insulin control is pivotal in weight management and GLP-1 drugs.
“So we have a molecule that survives the stomach.”
Examine the interaction between GLP-1 response and carbohydrate intake in obesity.
“This is something I've discussed previously.”
Explore the role of GLP-1 drugs in managing cravings and building habits.
“exert measurably less temptation than they otherwise would.”

Get the gist, explore an idea or ask about something said.
On The Metabolic Classroom with Dr. Ben Bikman, what are the key points of this episode?
Automatic transcript. May contain errors.
0:00Are GLP-1 pills just injectable drugs turned into tablets? Not exactly. Oral semaglutide is similar to the injectable version, but because your stomach naturally breaks down this type of drug, it needs a special ingredient to help it survive and get absorbed. That's why it has to be taken on an empty stomach with very little water. But another GLP-1 pill called orforglipron is different. It's a small molecule that can survive digestion on its own, so it can be taken more like a normal pill, with or without food. That could make GLP-1 drugs much easier to use. But the important part is this. Whether it comes as a pill or an injection, it doesn't change the basic rules of metabolism.
0:46These drugs can help you eat less, but insulin still plays the major role and whether your body stores fat or releases it. The drug may be changing a lot, but the metabolic rules are not. This is Lecture 162 of The Metabolic Classroom.
1:05Therapy's biggest impact doesn't show up in some dramatic breakthrough. It shows up in the smallest moments. You bite your tongue instead of escalating. You put your phone down instead of firing off that text. You say what you actually mean instead of what would hurt someone else the most. Nobody applauds those moments, but they quietly change your life. That's what growing feels like. And that's exactly what Grow Therapy is here for. Grow is therapy that works, covered by insurance. Sessions average$21 with insurance, and some pay as little as$0, depending on their plan. There are no subscriptions, no long-term commitments.
1:42You just pay per session. Grow connects you with thousands of high-quality, licensed therapists across the U.S., offering both virtual and in-person sessions, nights and weekends. You can search by what matters, like insurance, specialty, identity, or availability. And you can book a therapy session in minutes and begin in as little as two days, not the national 48-day average. See if you could pay as little as$0 for therapy in seconds at growtherapy.com. That's growtherapy.com. slash start now growtherapy.com slash start now availability and coverage vary by state and insurance plan this is hannah burner from giggly squad opil is the first over-the-counter daily birth control pill available in the u.s let's be real getting a birth control prescription is not always easy and it's so much admin in fact about a third of women face barriers to access prescription birth control between scheduling appointments missing work class or just trying to exist it's a lot but now opill is putting birth control in our control opill is a daily birth control that's fda approved full prescription strength and estrogen free and 98 effective when used as directed grab it online or at most major retailers no prescription or doctor's appointment needed so if you're thinking about birth control check out opill to see if it's right for you use code giggly for 25 off your first month of opill at opill.com that's code giggly at opill ZocDoc.com birth control in your control.
3:16We love to see it. This ad is sponsored by ZocDoc. Hi, it's Danny Pellegrino from Everything Iconic. Have you been putting off that annual doctor's appointment because you don't want to make the call? Or maybe you've been meaning to find a new dentist, but you have no idea where to start. I find that's especially true when you move. It's hard to find your people. I've been there, which is why I use ZocDoc. Now, as a busy podcaster parent and someone who's always juggling a million things. I love anything that makes life easier. And ZocDoc lets you search and compare local in-network doctors with over 250 ,000 providers across more than 200 specialties.
3:51You can read reviews from real patients, find a provider who feels like the right fit, see actual appointment openings, and book instantly. I recently had a last-minute health issue pop up and needed to see someone fast. And instead of calling around or sitting on hold, I found a doctor on ZocDoc and booked an appointment in just a few minutes. It made the whole process so much less stressful. Now taking care of your health just got easier. Download the ZocDoc app today. That's ZocDoc, Z-O-C-D-O-C, and book that appointment on your to-do list.
4:31Welcome back to the Metabolic Classroom. I'm Ben Bickman, metabolic scientist and professor of cell biology. There are now two GLP-1 pills approved for weight loss, and I keep getting the same question about them. Are these just the injection in a tablet? The answer is that one of them kind of is, but the other one is not at all. One is the same peptide that has always been in the syringe. It's carried across the stomach in this case, but it has a chemical helper, and it's been dosed in a very, very different way as we'll get into in a moment. The other molecule is not a peptide at all. It is in fact what's called a small molecule and it attaches to a different part of the same receptor and does not have the exact same signaling, but it's close enough that it works.
5:24That difference is significant and it changes how these drugs are taken and at what doses. What it does not change is anything about how the body actually stores and releases fat. And that's what we'll end with. Okay, before we get to the pills, let's just be clear about what GLP-1 is because it helps us make sense of these drugs. As you know by now, I'm sure, but I'm going to be a thorough professor and remind you of it anyway, GLP-1 is a hormone made by cells that line your intestine. And they are normally, this is released as food comes down the intestines. It does a couple things at the same time.
6:05In fact, it does a lot of different things. But with regards to weight loss and obesity, the most relevant one of all is that it slows the rate at which the stomach empties into the intestine. So in other words, the rate at which nutrients from your meal actually get into your blood is greatly diminished. So there's this significant downstream slowing down. The secondary effect is that it can change appetite regulation in the brain. That's a little more debated, actually, that there's some evidence to suggest that might not be so relevant of a mechanism. But until that's been really proven otherwise, I think we can still consider it a mechanism.
6:51All right, so let's get to the two molecules, the structural chemical point. GLP-1 is a peptide, which means that it's a short chain of amino acids. These are the same building blocks that make up every protein we eat or every protein hormone that our body makes. That's a protein-based or a peptide-based. The drugs are built to imitate that peptide signal, and the drugs specifically designed as peptides to match the peptide, similarly match the peptide structure of GLP-1 itself, are the ones you've heard about. Semaglutide or the older one, liraglutide, or the newer one, terzepatide, or the newer one still, retitrutide.
7:38All of these are peptides. they they're designed to last a little longer and be a little more stable than the natural version of the hormone but it is still a chain of amino acids that's a problem because the entire purpose of the stomach is to destroy um these types of these types of molecules it they the The stomach is built to destroy peptides. The stomach acid is very acidic. The pH is extremely low, which means it's very acidic, like roughly similar to the acidity of battery acid. And it works very well at opening proteins up. So when you eat a protein, the stomach acid helps denature or unfold the protein.
8:29That then helps it be in a position where enzymes can come and split up the protein. So the enzymes are ready to go, but they need the protein to be opened up. So if you swallow a peptide drug and it just gets straight to your stomach as it is, it's not going to get into your blood as the peptide that you took it in. It's just going to become this random bunch of amino acids that your body will do whatever it wants with. So if you just swallow a straight peptide, what will end up in your blood are the individual amino acids. And, you know, almost no chance that it would ever get rebuilt as the specific protein you just ate.
9:13So for most of the history of this class of drugs for peptides, the answer has always been a needle. because if you inject it into the body, it can bypass that digestive complication entirely. Okay, now what about the drug then? How does the drug get around this? Oral semaglutide is the exception. It's still a peptide and it's interesting and helpful, I think, to understand how the workaround is worked out because the compromises show up. This is what you actually see in some of the instructions on the bottle. So the tablet will contain semaglutide, and it contains a much larger quantity of a second compound.
9:59And it's what's called an absorption enhancer, abbreviated as S-N-A-C, or we'll just call it SNAC. That second compound does three things in the stomach, this absorption enhancer. First, it buffers the acidity immediately around the tablet. So it makes it so that right around the tablet, the stomach acid isn't quite as acidic. So it helps the protein, the denaturing or the unfolding of the protein not work as well. Second, this absorption enhancer also keeps the semaglutide molecules from clumping together because the clumps can't be absorbed if it's all clumped up, but the individual molecules can.
10:44So it separates them out. And then third, final part of this absorption enhancer is that it can temporarily slightly loosen the membrane of the stomach lining so that the molecule has a better chance of getting through the stomach. That last detail is a unique one. Almost every drug you swallow is absorbed further down the digestive tract in the small intestine. That's where the lining is a little thinner. You don't have that big, thick mucosal lining, and there's much more surface area as the molecule's moving through the small intestine. But this one is absorbed in the stomach. The stomach does not have a lot of absorptive capacity or surface compared to the intestine.
11:27And so even with all of that engineering that I just mentioned, even with all that absorption enhancing, only about 1 % of the dose you take in actually reaches the bloodstream. And depending on conditions, it might even be lower than that. It can be closer to a half a percent. Almost the entire dose is destroyed or just passes right through. This is what you see on the label of the drug. The tablet needs to be taken in the morning on an empty stomach with just a little bit of water, just a few ounces of water. And you're not eating anything else for a period of time. You're not drinking anything else for a period of time.
12:05It's about, you know, 30 or so minutes. If you have anything else in the stomach at the time, it disrupts everything that the absorption enhancer, SNAC, is trying to create. All right, so that is when the injectable drug, semaglutide, is used in an oral version. Now let's talk about a different one. Orforaglipron, this is sold as a drug called Foundeo by Lilly. Orforaglipron takes a different approach because it abandons the peptide problem altogether. It avoids it. So it circumvents the peptide problem by just abandoning being a peptide. This is what chemists call a small molecule. It's closer in kind to something like antihistamine than it is to generally like a hormone.
12:56It doesn't have an amino acid chain that the stomach can cut. So the acid and the enzymes have nothing to work on. It simply remains intact as you take it in. Now, I know what you're thinking. If this molecule looks nothing like GLP-1, the peptide, how does it actually activate the receptor? Well, the answer is that it does not bind where GLP-1 binds. It still activates the GLP-1 receptor, but it does so at a distinct attachment point. So it's going to active and give the same effect, but it does so by, if you will, knocking on a different door of the cell. Or it knocks on the same door, but it's not knocking on the door, it's ringing the doorbell.
13:40But all of this to say, I'm trying to think of a metaphor where it is still the same receptor, but it's being activated in a slightly different way. So we would say in one case, it's knocking on the door. In the other case, it's just ringing the doorbell. The door is still going to open. All right. In a study that measured this most directly, they used what's called a tracer method. and they labeled this small molecule. So orforaglipron was labeled or tagged in a way as a molecule that they could see where it goes in the body. And they compared that oral ingested way with an intravenous or an injection.
14:19And they found that about almost 80 % of the oral dose that was taken got into the bloodstream. Now, again, compare that to the 1 % for the oral semaglutide. I mean, that's a pretty enormous difference. So the drug stays in the body long enough also that you can just have a once daily dose. The fact that you can take it with food is helpful. There's some evidence to show that if you do take it with food, it can lower that by a little bit. It can go to about 80 % of its 100 % absorption. so it can be diminished a bit, but it still falls within a range of a meaningful physiological response. So that means with the orophoraglopron, the person doesn't have to worry about the absorption enhancer.
15:08They don't have to worry about taking it on an empty stomach. There's no waiting period. They can take it any time of the day with any amount of food. Okay, now let's just revisit the metabolic actions here. Of course, no surprise with you knowing what you do about me, I need to talk about insulin. But that's because we're talking about drugs that induce weight loss. So it's not inappropriate to bring up insulin because insulin is the master metabolic hormone that controls the growing and the shrinking of fat cells. So what happens to insulin and other related metabolic outcomes? There is a 26-week trial in adults with type 2 diabetes that compared this.
15:48It compared orforaglopron against placebo and against an injectable GLP-1 drug. Markers of insulin sensitivity improved with the standard fasting index of insulin resistance falling by up to about, it was about a quarter, about 25 % at week 26. And also adiponectin, which is a very friendly hormone, it's released from healthy fat cells that improves insulin sensitivity, also increased. Now let's get into some additional studies there are other studies that have looked at they've expanded the results and done more direct drug comparisons but when i mention these i just want to help you understand some of the scientific record keeping that happens here in these kinds of studies there are two ways the scientists can track and analyze the results one way counts everyone who was randomized whether or not they stayed on the drug.
16:49The other will count only what happened in the people who stayed on the drug. So the first number is always going to be more modest, but it's also, it's more conservative, but it's also more reflective of a real world population because sometimes people get off the drug. So I'm going to rely on that one. All right. So the main obesity trial enrolled a pretty significant number of people, about 3 ,000 adults with obesity and without diabetes, and they ran for 72 weeks. Weight fell by 7.5 % at the lowest dose, 8.5 % at the middle dose, and just over 11 % at the highest dose against a loss of just about 2 % on placebo.
17:34And then among people who stayed on the highest dose, the figure was a little over 12%. So it was a bit more. Now, there's also a head-to-head trial in type 2 diabetes where orforglupron, the small molecule, was tested against the oral semaglutide. And orforglupron won on blood sugar and on weight. But the dose wasn't totally comparable. The oral semaglutide doses in that trial were the 7 and the 14 milligram dose, which are the diabetes doses. As you know, I've articulated this before, semaglutide has been traditionally used at lower doses when it was just used for controlling diabetes, but its obesity dose is more significant.
18:20So the dose approved for obesity is 25 milligrams. So the trial did not test the two drugs at a dose that people would normally be taking for weight loss. When you look at the obesity trials instead, each drug against placebo in people with obesity and without diabetes, the oral semaglutide at the obesity dose produced about 13.5 % weight loss, and the orforaglupron produced about 11%. percent.
18:51Therapy's biggest impact doesn't show up in some dramatic breakthrough. It shows up in the smallest moments. You bite your tongue instead of escalating. You put your phone down instead of firing off that text. You say what you actually mean instead of what would hurt someone else the most. Nobody applauds those moments, but they quietly change your life. That's what growing feels like. And that's exactly what Grow Therapy is here for. Grow is therapy that works, covered by insurance. Sessions average$21 with insurance and some pay as little as$0 depending on their plan. There are no subscriptions, no long-term commitments.
19:28You just pay per session. Grow connects you with thousands of high-quality licensed therapists across the U.S. offering both virtual and in-person sessions, nights and weekends. You can search by what matters, like insurance, specialty, identity, or availability. And you can book a therapy session in minutes and begin in as little as two days, not the national 48-day average. See if you could pay as little as$0 for therapy in seconds at growtherapy.com slash start now. That's growtherapy.com slash start now. growtherapy.com slash start now. Availability and coverage vary by state and insurance plan.
20:09If you felt stuck trying to lose weight, you're not alone. Enter Weight Loss by HERS. It's designed to support you in reaching your goals. And HERS now offers access to an affordable range of FDA-approved GLP-1 medications, including the WeGovi pill and the WeGovi pen. Even better, with a range of affordable GLP-1 options, HERS makes it simple to find an approach that fits your needs and your budget, if eligible. You'll get a treatment plan personalized to you and unlimited dosage changes as needed. It's weight loss designed to work with your life. Ready to reach your goals? Visit ForHERS.com slash eligible to get personalized, affordable care that gets you.
20:47That's F-O-R-H-E-R-S dot com slash eligible. ForHERS.com slash eligible. Weight loss by HERS is not available in all 50 states. WeGovi is the registered trademark of Novo Nordisk AS. To get started and learn more, including important safety information, Wegovi clinical study information and restrictions, visit ForHers.com.
21:12So pretty good, pretty comparable weight loss. The peptide one in that case, the semaglutide with its absorption enhancer did beat that out. But you could say it was still close. However, in this case, interestingly, the negative side effects, the tolerability were a little more negative on the orforglopron. And that's the same side effects that you'd see with semiglutide, the nausea, the vomiting, the diarrhea. So I think this summary here would be that the small molecule performs better on blood sugar in diabetes at the doses that were tested in that one study. So a more modest semiglutide dose.
21:51The peptide produces a little more weight loss when it's head to head at weight loss dosing. But the small molecule is a lot easier to take, and so maybe it has a higher real-world adherence. Okay, there's one more. Researchers took nearly 400 people who had completed a long course of injected semaglutide or injected terzepatide, and they'd reached a stable weight. And then they moved them off the injected peptide and then moved them either onto or for glopron or onto placebo for a year. So they started on the injected peptide. Then they switched them over to the small molecule or placebo. The people that were switched to the small molecule held up about almost 80 to 90 % of their weight loss.
22:43They kept it. but the people switched to placebo, they kept only half that weight loss. So in other words, they gained about half back. So let me say that all another way. The people that were on the injectable and switched over to the oral small molecule gained back about 10 %-ish of their weight, but the other group switched over to placebo, gained back about half of their weight. And so that's pretty meaningful. And it might be powerful in light of my final point here, which is the timing of all this thing. So we have a molecule that survives the stomach. It's absorbed about 80 times more efficiently as the peptide version.
23:23You don't have to worry about fasting. You can take it with food. That is a very convenient advancement. And the convenience, I think, is relevant because it may determine whether someone stays on the drug. But there are still these fundamental, not a but, I would just say nevertheless, we need to keep the fundamental metabolic rules in mind. Insulin still governs whether fat cells are shrinking or growing. As long as insulin is elevated, stored fat stays stored. No amount of GLP-1 drug can change that physiological, biochemical cell biology. What the drugs do is lower insulin directly, especially by changing how much a person eats and how much what they eat is getting into the blood.
24:12now when i say what the person eats refined carbohydrate is the most powerful driver of insulin since it's flour sugar and the processed starches that are built from them that push insulin higher and hold it up longer than anything else the person is going to eat or drink so if a drug is making it easier to eat less the thing to eat less of is refined carbohydrate. This is something I've discussed previously. Researchers 30 years ago compared women with obesity to lean women matched for age, and they gave both groups an oral carbohydrate load and on one occasion, a big fat load. So they had a high carb meal and a high and then a low carb, high fat meal.
25:02And following the gut, they looked at the gut response over three hours, how much it produced GLP-1. In the women with obesity, the GLP-1 response to carbohydrate was essentially non-existent. It was markedly blunted, we would say in scientific terms, but it didn't reach a point of statistical significance at all. But the response to fat was more robust and it tended to follow similar, more in line with the lean women. So the impairment to GLP-1 response was unique to the carbohydrate in some of these women. The macronutrient that raises insulin the most is therefore also the one that has stopped producing a satiety signal in the form of GLP-1 in the people eating the most of it.
25:51Remember, it was just the women with obesity that had this effect. So they would want to eat more carbohydrates. The hormone that would normally help them regulate that, the GLP-1, was blunted. It wasn't working so well. A GLP-1 drug gives in the pill, I think what it can help do is restore the GLP-1 response. So just to keep this in mind, whether it's the oral delivery or whether it's an injectable, we want to keep in mind that the drug should be used not for weight loss per se, even if that is the foundational justification for it. It should be used to help someone learn to control their cravings for carbohydrates.
26:33And I also think there's a window in which that can work better. There's a two-year semaglutide trial, and they measured cravings for sweets and refined starches and sugars. And they found that at about six months, cravings were significantly blunted. At one year, the cravings were still blunted. And then at about two years, the cravings had returned to normal, despite ongoing and even escalation of the dose of the GLP-1 drug. In other words, the reduced pull or cravings of the sweet food, it faded even while the person was still on the drug. This is what an economist may refer to as diminishing returns.
27:15So there's roughly a year, maybe a little more, during which sugar and foods built on that sugar.
27:25Therapy's biggest impact doesn't show up in some dramatic breakthrough. It shows up in the smallest moments. You bite your tongue instead of escalating. You put your phone down instead of firing off that text. You say what you actually mean instead of what would hurt someone else the most. Nobody applauds those moments, but they quietly change your life. That's what growing feels like. And that's exactly what Grow Therapy is here for. Grow is therapy that works, covered by insurance. Sessions average$21 with insurance and some pay as little as$0 depending on their plan. There are no subscriptions, no long-term commitments.
28:02You just pay per session. Grow connects you with thousands of high-quality, licensed therapists across the U.S., offering both virtual and in-person sessions, nights and weekends. You can search by what matters, like insurance, specialty, identity, or availability. And you can book a therapy session in minutes and begin in as little as two days, not the national 48-day average. See if you could pay as little as$0 for therapy in seconds at growtherapy.com slash start now. That's growtherapy.com slash start now. growtherapy.com slash start now. Availability and coverage vary by state and insurance plan.
28:44If you felt stuck trying to lose weight, you're not alone. Enter Weight Loss by HERS. It's designed to support you in reaching your goals. And HERS now offers access to an affordable range of FDA-approved GLP-1 medications, including the WeGovi pill and the WeGovi pen. Even better, with a range of affordable GLP-1 options, HERS makes it simple to find an approach that fits your needs and your budget. If eligible, you'll get a treatment plan personalized to you and unlimited dosage changes as needed. It's weight loss designed to work with your life. Ready to reach your goals? Visit ForHERS.com slash eligible to get personalized, affordable care that gets you.
29:21That's F-O-R-H-E-R-S dot com slash eligible. ForHERS.com slash eligible. Weight loss by HERS is not available in all 50 states. WeGovi is the registered trademark of Novo Nordisk AS. To get started and learn more, including important safety information, WeGovi clinical study information, and restrictions, visit ForHERS.com.
29:45exert measurably less temptation than they otherwise would. And that period is, I think, the window. Someone who spends that time eating smaller portions of the same food will lose weight and leave all the other habits, though, unchanged. And when the cravings start to return, they go right back to them. So what they need to do during this time when the cravings for these refined carbohydrates is turned down is use that as an opportunity to build new habits. And when you do eat, you're focusing on foods like fat and protein. And then you're not having to worry about the diminishing returns of this turned down carb craving.
30:26When the cravings would start to come back, well, hopefully they don't because the person has learned a little bit of discipline. This, I think, might... It will be interesting to see how studies come out in the next years But this idea of someone being on the injectable and then switching off the injectable to the oral small molecule, I can't help but wonder whether that allows the person to more effectively cycle off and help retain a higher efficacy or a higher sensitivity to the drug. But remember, all of it is with the purpose. It should be with the purpose of learning to control your habits.
31:08No one wants to stay walking around with a crutch. They hurt their knee. Well, they're on a crutch until that knee is strong enough to get them off it. I think the same thing should be done with these GLP-1 drugs. They're a crutch. No one wants to be on a crutch forever. You shouldn't need to. You should be hoping to get strong enough to walk again on your own. That, to me, I think is the best view with these GLP-1 drugs. You need a little help to control your cravings for carbohydrates. You've not been able to do it on your own because, dare I say, you have an addiction. It can be difficult to break an addiction on your own.
31:47The drug can help break that addiction where you are now using it more strategically with, again, with the intention being, this is helping me control my cravings for carbohydrates. You learn what that feels like, what that looks like. and then someday you have an off-ramp on that drug where maybe about a year in or so, you say, I know I'm going to start losing some efficacy here. I need to be thinking of my habits changing. Maybe that gives you an opportunity to reduce the dose and then eventually get off the drug. Just like someone with a knee injury wants to get off the crutch. All right, let's wrap this up.
32:26Oral semaglutide is close to the thing that people imagine when they say Ozempic, you can swallow, quote unquote. It's the same peptide. It's just escorted through the stomach with some clever chemistry, with some absorption enhancing, but it's at the cost of some convenience. It's a very strict routine of what you can eat or drink around it, but the small molecule is different or forglopron. It's not a peptide. It has a different way of activating GLP-1, a different way of getting into your blood that makes it a lot more convenient, but it does appear to have slightly more of the negative consequences like the nausea and the vomiting.
33:08So the chemistry can change between the molecules, but even still, the metabolic rules do not. These must be, or ideally, they are used as a way to help lower your insulin by helping you learn to control your cravings. Class dismissed. Until next time, more knowledge, better health.
33:40This is Hannah Berner from Giggly Squad. O-Pill is the first over-the-counter daily birth control pill available in the U.S. Let's be real. Getting a birth control prescription is not always easy, and it's so much admin. In fact, about a third of women face barriers to access prescription birth control between scheduling appointments, missing work, class, or just trying to exist. It's a lot. But now Opil is putting birth control in our control. Opil is a daily birth control that's FDA approved, full prescription strength, and estrogen free, and 98 % effective when used as directed. Grab it online or at most major retailers, no prescription or doctor's appointment needed.
34:19So if you're thinking about birth control, check out Opil to see if it's right for you. Use code GIGLY for 25 % off your first month of Opil at opill.com. That's code giggly at opill.com. Birth control in your control. We love to see it.
Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind
📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com
In today’s mini-lecture, Dr. Ben Bikman explains the new generation of oral GLP-1 medications and why two drugs that come as pills can work very differently. Oral semaglutide is still a peptide, so it requires a special absorption enhancer to protect it from digestion and help it cross the stomach lining. Even then, only about 1% of the dose reaches the bloodstream, requiring strict instructions about taking it on an empty stomach. Orforglipron, by contrast, is a small molecule rather than a peptide, allowing it to survive digestion and be absorbed much more efficiently without the same restrictions.
Ben reviews studies comparing the drugs for blood glucose control, weight loss, side effects, and maintaining weight loss after injectable GLP-1 therapy. But he emphasizes that changing the delivery method does not change the underlying metabolic rules: insulin still governs whether fat is stored or released.
Most importantly, Ben argues that GLP-1 medications should be viewed as an opportunity to change metabolic habits rather than simply as long-term weight-loss drugs. Because they can temporarily reduce cravings for sweets and refined carbohydrates, he believes that window should be used to reduce those foods, emphasize protein and fat, and develop habits that can eventually provide an “off-ramp” from the medication..
References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com
NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.
#GLP1 #GLP1Medications #OralGLP1 #Orforglipron #Semaglutide #WeightLoss #InsulinResistance #Insulin #MetabolicHealth #WeightLossMedication #GLP1WeightLoss #CarbCravings #BloodSugar #Type2Diabetes #Metabolism #LowCarb #DrBenBikman #MetabolicClassroom #MetabolismMatters #HealthScience
Hosted on Acast. See acast.com/privacy for more information.